Research ArticleOriginal Research

Azithromycin for Bronchial Asthma in Adults: An Effectiveness Trial

David L. Hahn, Mike Grasmick, Scott Hetzel and Steven Yale
The Journal of the American Board of Family Medicine July 2012, 25 (4) 442-459; DOI: https://doi.org/10.3122/jabfm.2012.04.110309

References

  1. 1.↵
    1. Richeldi L,
    2. Ferrara G,
    3. Fabbri LM,
    4. Lasserson TJ,
    5. Gibson PG
    . Macrolides for chronic asthma. Cochrane Database Syst Rev 2005;(3):CD002997.
  2. 2.↵
    1. Altenburg J,
    2. de Graaff CS,
    3. van der Werf TS,
    4. Boersma WG
    . Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011;81:67–74.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Johnston SL,
    2. Martin RJ
    . Chlamydophila pneumoniae and Mycoplasma pneumoniae. A role in asthma pathogenesis? Am J Respir Crit Care Med 2005;172:1078–89.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Herland K,
    2. Akselsen J-P,
    3. Skjønsberg OH,
    4. Bjermer L
    . How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005;99:11–9.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Travers J,
    2. Marsh S,
    3. Williams M,
    4. et al
    . External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007;62:219–23.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Demoly P,
    2. Gueron B,
    3. Annunziata K,
    4. Adamek L,
    5. Walters RD
    . Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010;19:150–7.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Global Initiative for Asthma (GINA) 2007. Global Strategy for Asthma Management and Prevention. Updated 2007. GINA Executive Committee, 92 pages.
  8. 8.
    American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am J Resp Dis 1991;144:1202–18.
    OpenUrl
  9. 9.
    1. Dekker FW,
    2. Schrier AC,
    3. Sterk PJ,
    4. Dijkman JH
    . Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. Thorax 1992;47:162–6.
    OpenUrlAbstract/FREE Full Text
  10. 10.
    1. Juniper EF,
    2. Buist AS,
    3. Cox FM,
    4. Ferrie PJ,
    5. King DR
    . Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115:1265–70.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.
    1. Juniper EF,
    2. O'Byrne PM,
    3. Guyatt GH,
    4. Ferrie PJ,
    5. King DR
    . Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902–7.
    OpenUrlAbstract/FREE Full Text
  12. 12.
    1. Juniper EF,
    2. O'Byrne PM,
    3. Roberts JN
    . Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? Respir Med 2001;95:319–23.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Hahn DL
    . An unanticipated effect of clinical trial registration. BMJ [serial online] Available from: http://www.bmj.com/content/325/7376/1314?tab=responses, 2007. Accessed April 27, 2012.
  14. 14.↵
    1. Juniper EF,
    2. Guyatt GH,
    3. Willan A,
    4. Griffeth LE
    . Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol 1994;47:81–7.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Peters SP,
    2. Kunselman SJ,
    3. Icitovic N,
    4. et al
    . Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715–26.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Smith DH,
    2. Malone DC,
    3. Lawson KA,
    4. Okamoto LJ,
    5. Battista C,
    6. Saunders WB
    . A national estimate of the economic cost of asthma. Am J Resp Crit Care Med 1997;156:787–93.
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Shoji T,
    2. Yoshida S,
    3. Sakamoto H,
    4. Hasegawa H,
    5. Nakagawa H,
    6. Amayasu H
    . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950–6.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Amayasu H,
    2. Yoshida S,
    3. Ebana S,
    4. et al
    . Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000;84:594–8.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Black PN,
    2. Blasi F,
    3. Jenkins CR,
    4. et al
    . Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001;164:536–41.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Kraft M,
    2. Cassell GH,
    3. Pak J,
    4. Martin RJ
    . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Effect of clarithromycin. Chest 2002;121:1782–8.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Kostadima E,
    2. Tsiodras S,
    3. Alexopoulos EI,
    4. et al
    . Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004;23:714–7.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Hahn DL,
    2. Plane MB,
    3. Mahdi OS,
    4. Byrne GI
    . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006;1:e11.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Piacentini GL,
    2. Peroni DG,
    3. Bodini A,
    4. et al
    . Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007;28:194–8.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Simpson JL,
    2. Powell H,
    3. Boyle MJ,
    4. Scott RJ,
    5. Gibson PG
    . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148–55.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Strunk RC,
    2. Bacharier LB,
    3. Phillips BR,
    4. et al
    . Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008;122:1138–44.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Sutherland ER,
    2. King TS,
    3. Icitovic N,
    4. et al
    . A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747–53.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. von Hertzen L,
    2. Vasankari T,
    3. Liippo K,
    4. Wahlström E,
    5. Puolakkainen M
    . Chlamydia pneumoniae and severity of asthma. Scand J Infect Dis 2002;34:22–7.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Hahn DL,
    2. Golubjatnikov R
    . Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 1992;12:945–7.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Pasternak R,
    2. Huhtala H,
    3. Karjalainen J
    . Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. J All Clin Immunol 2005;116:1123–8.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Brandén E,
    2. Koyi H,
    3. Gnarpe H,
    4. Tornling G
    . Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. Respir Med 2005;99:20–6.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Hahn DL
    . Infectious asthma: a reemerging clinical entity? J Fam Pract 1995;41:153–7.
    OpenUrlPubMed
  32. 32.↵
    1. Grayston JT,
    2. Kronmal RA,
    3. Jackson LA,
    4. et al
    . Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:1637–45.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. O'Connor CM,
    2. Dunne MW,
    3. Pfeffer MA,
    4. et al
    . Azithomycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial. JAMA 2003;290:1459–66.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Albert RK,
    2. Connett J,
    3. Bailey WC,
    4. et al
    . Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689–98.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Hahn DL
    . Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:2235–7.
    OpenUrlPubMed
  36. 36.↵
    1. Schentag JJ,
    2. Ballow CH
    . Tissue-directed pharmacokinetics. Am J Med 1991;91:5S–11S.
    OpenUrlPubMed
  37. 37.↵
    1. Ebell MH,
    2. Siwek J,
    3. Weiss BD,
    4. et al
    . Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17:59–67.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Hahn DL
    . Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J Fam Pract 1995;41:345–51.
    OpenUrlPubMedWeb of Science
  39. 39.↵
    1. Aronson N,
    2. Lefevre F,
    3. Piper M,
    4. et al
    . Management of chronic asthma. Evidence report/technology assessment number 44. AHRQ publication no. 01-E044. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
  40. 40.↵
    1. Tunis SR,
    2. Stryer DB,
    3. Clancy CM
    . Practical clinical trials. Increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624–32.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Thorpe KE,
    2. Zwarenstein M,
    3. Oxman AD,
    4. et al
    . A pragmatic - explanatory continuum indicator summary (PREVIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464–75.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Rollins DR,
    2. Beuther DA,
    3. Martin RJ
    . Update on infection and antibiotics in asthma. Curr Allergy Asthma Rep 2010;10:67–73.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section